AlphaStocks
5.0
Consider Buy

Adma Biologics, Inc. (ADMA)

As of Sep 21, 2026, Adma Biologics, Inc. (ADMA) scores 5.0/10 on AlphaStocks' five-model composite, #109 of 168 Health Care stocks. At $9.13, ADMA trades 32% below its model fair value of $13.

Health Care / Biotechnology

S&P SmallCap 600

$9.13

Below average on several measures. Research carefully.

Consider Buy

Score based on 4 of 5 models — moderate confidence

Data as of Sep 21, 2026

#109out of 168 in Health Care

Is ADMA BIOLOGICS, INC. a Good Investment in 2026?

ADMA BIOLOGICS, INC. (ADMA) scores 5.0 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Buffett model rates ADMA BIOLOGICS, INC. as Strong. However, the Graham model rates it Caution — 50% above fair value. ADMA BIOLOGICS, INC. currently trades 32% below its estimated fair value of $13. ADMA BIOLOGICS, INC. ranks #109 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E15.2ROE22.0Market Cap2B

Estimated Fair Value

$13.4832% below

Trading below estimated fair value. ROE of 22% signals strong profitability. P/E of 15x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Strong

Business quality & competitive moat

Graham

Caution

50% above fair value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Strong

Earnings yield 8.7% · ROC 41%

Frequently Asked Questions

Is ADMA BIOLOGICS, INC. (ADMA) a good investment?
As of Sep 21, 2026, Adma Biologics, Inc. (ADMA) scores 5.0/10 on AlphaStocks' five-model composite, #109 of 168 Health Care stocks. At $9.13, ADMA trades 32% below its model fair value of $13. That score is below average, suggesting caution.
What is ADMA BIOLOGICS, INC.'s Piotroski F-Score?
ADMA BIOLOGICS, INC.'s Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is ADMA overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $13, ADMA appears undervalued. The stock currently trades 32% below its estimated fair value. Trading below estimated fair value. ROE of 22% signals strong profitability. P/E of 15x is moderate for this quality level.
How does ADMA compare to other Health Care stocks?
ADMA BIOLOGICS, INC. ranks #109 out of 168 stocks in the Health Care sector, placing it in the top 65% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about ADMA?
AlphaStocks evaluates ADMA using five proven investment models. Piotroski: Attractive; Buffett: Strong; Graham: Caution; Greenblatt Magic Formula: Strong. These models are combined into a single composite score of 5.0/10.

Similar Stocks

ABBVINCYHRMY

Compare ADMA with

ABBV vs ADMAADMA vs INCYADMA vs HRMYADMA vs VALADMA vs PARR

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer